Search
multitarget stool RNA; mt-sRNA (Colosense)
Indications:
- screening for colon cancer (FDA-approved 2024) [2]
Procedure:
- tests patients' stool for
- hemoglobin
- neoplasia-associarws RNA
Interpretation:
- among average-risk patients, sensitivity for multitarget stool RNA is
- 94% for colorectal cancer
- 100% for stage I/II colorectal cancer
- 92% for stage III/IV colorectal cancer
- 65% for >= 10 adenomas or lesions with high-grade dysplasia
- 47% for tubulovillous adenomas
- 42% for serrated adenomas or tubular adenomas >= 1 cm [1]
- specificity for multitarget stool RNA is 85% [1]
- 88% specificity for no lesions on colonoscopy
General
molecular diagnostic test
RNA testing
hemoglobin in stool
References
- Barnell EK, Wurtzler EM, La Rocca J et al
Multitarget Stool RNA Test for Colorectal Cancer Screening.
JAMA. Published online October 23, 2023.
PMID: 37870871
https://jamanetwork.com/journals/jama/fullarticle/2811133
- Brooks, M
FDA OKs First Multitarget Stool RNA Test for CRC Screening.
Medscape. May 07, 2024
https://www.medscape.com/viewarticle/fda-oks-first-multitarget-stool-rna-test-crc-screening-2024a10008tu